Publications:
Evaluation of Therapies for Secondary Hyperparathyroidism
Kidney Dis 2023;9:206–217
Real‑world assessment: effectiveness and safety of extended‑release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
Germain et al. BMC Nephrology (2022) 23:362
REsCue trial:Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients
Am J Nephrol 2019;49:281–283
Aiming Too Low: Reevaluation of Target Concentrations of Serum 25-Hydroxyvitamin D in Secondary Hyperparathyroidism
Nutrition 107(2023)111899
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease
Am J Nephrol 2019;49:284–293
Extended-Release Calcifediol in Renal Disease
Vitamin D, Volume 2: Health, Disease and Therapeutics, Fourth Edition 2018; 667-678
Extended-Release Calcifediol for Secondary Hyperparathyroidism
in Stage 3-4 Chronic Kidney Disease.
Expert Rev Endocrinol Metab 2017
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism
in Stages 3 and 4 Chronic Kidney Disease.
Am J Nephrol. 2016;44(4):316-325. Epub 2016 Sep 28.
Extended-Release Calcifediol Found Safe, Effective for SHPT
Renal & Urology News
Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism
Associated with Vitamin D Insufficiency in Chronic Kidney Disease
Am J Nephrol 2014;40:535–545
Modified-release oral calcifediol corrects vitamin D insufficiency
with minimal CYP24A1 upregulation
Journal of Steroid Biochemistry & Molecular Biology (2015) |
